Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB128
- Development stage
- Preclinical
- Lead developer
- BiomeBank
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
BB128 is an investigational live biotherapeutic product (microbial consortium therapy) being developed by BiomeBank. Developed using BiomeBank's proprietary CONSORTIOME platform, BB128 consists of a defined, cultured microbial consortium designed to modulate the gut microbiome. It is currently in preclinical (in vitro) development for the treatment of an undisclosed rare/orphan disease, with an orphan drug designation pending. Historically, some public sources and regulatory reports (such as the World Health Organization's antibacterial pipeline reviews) have associated the code BB128 with BiomeBank's donor-derived fecal microbiota transplantation (FMT) product, Biomictra, which is approved in Australia for recurrent Clostridioides difficile infection. However, current pipeline information indicates BB128 is a distinct, defined cultured consortium therapy being developed for rare disease indications.
- Brand names
- BIOMICTRA
- Other names
- faecal microbiotafaecal microbiota (frozen)donor-derived faecal microbiota transplantationBiomeBank FMTBiomictra FMT
02
Targets
Dysbiotic gut microbial community in the colon
Beyond the preview
Go deeper on BB128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB128.